Total
0
Shares
MGC Pharmaceuticals (ASX:MXC) - CEO and Managing Director, Roby Zomer
CEO and Managing Director, Roby Zomer
Source: MGC Pharmaceuticals
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • MGC Pharmaceuticals (MXC) completes production of the €650,000 (A$1.01 million) ArtemiC order from Swiss PharmaCan (SPC)
  • MGC Pharma expects to receive the full amount by early December, delivering its best quarter and half-yearly revenue result as of December 31, 2021
  • ArtemiC is MGC’s natural, immune-modulation formaula that is made up of Vitamin C and herbal extracts used to treat anti-inflammatory illnesses
  • Further ArtemiC orders are set to continue following the grant of the Certificate of Free Trade in Germany and the EU in September 2021
  • MGC Pharma ends the day in the grey with shares trading at 4.5 cents

MGC Pharmaceuticals (MXC) has completed production of the €650,000 (A$1.01 million) ArtemiC order from Swiss PharmaCan (SPC).

MGC Pharma expects to receive the full amount by early December, delivering its best quarter and half-yearly revenue result as of December 31, 2021.

ArtemiC is made up of artemisinin, a drug from a fern-like plant that is used against malaria, and curcumin, a chemical that aids in anti-inflammatory and antioxidants.

It is then mixed with Vitamin C and boswellia serrata, a herbal extract used to treat inflammatory illnesses.

Further ArtemiC orders are set to continue following the grant of the Certificate of Free Trade in Germany and the EU in September 2021.

Managing Director and Co-Founder Roby Zomer commented on the agreement.

“The partnership between MGC and Swiss PharmaCan has been a cornerstone for MGC’s continued for MHC’s continued sales and revenue growth in 2021 in the European market for its COVID-19 treatment ArtemiC,” Mr Zomer said.

“With the continuing outbreaks of COVID, not only in Europe but globally, we expect to see continued growth in the demand for COVID-19 treatments for those people who contract the disease.”

“MGC believes that its COVID-19 treatments are a cost-effective alternative which will assist the public health system manage the growing number of patients requiring medical intervention.”

MGC Pharma has ended the day in the grey, with shares trading at 4.5 cents in a $108.1 million market cap.

MXC by the numbers
More From The Market Herald

" RocketBoots (ASX:ROC) lists on ASX after $4.25m IPO

Software company RocketBoots (ROC) has debuted on the ASX today after raising $4.25 million through an initial public offer (IPO).

" Gladiator Resources (ASX:GLA) begins exploration at Minjingu

Zeus Resources, a wholly-owned subsidiary of Gladiator Resources’ (GLA), has begun exploration activities at the Minjingu Uranium Project.
Mineral Commodities (ASX:MRC) - CEO, Jacob Deysel

" Mineral Commodities (ASX:MRC) updates MRE at Tormin Inland Strands

Mineral Commodities (MRC) has updated the mineral resource estimate (MRE) for the Western Strandline at the Tormin Inland Strands deposit in South Africa.

" IODM (ASX:IOD) secures new revenue opportunity from WUBS partnership

Software solution company, IODM (IOD) has received a new revenue opportunity from its existing partnership with Western Union Business Solutions (WUBS).